基于算法的化学放射选择的前性研究,以优化高级头癌的治疗强度
Takahiro Hongo1, Yusuke Hirano1, Yu Tarutani1
1Departments of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
Oral oncology
|August 8, 2025
概括
这项研究开发了一种算法,以个性化化疗用于头癌,通过量身定制治疗强度来改善生存率和生活质量. 这种方法为标准的高剂量西斯替代方案提供了替代方案.
科学领域:
- 在瘤学瘤学.
- 头部和部癌症研究研究
- 化疗和辐射疗法治疗.
背景情况:
- 与高剂量西斯普拉丁化学放射治疗相比,局部发达的头平细胞癌 (LA-HNSCC) 治疗需要降低毒性.
- 目前标准的高剂量西斯 (CDDP) (100 mg/m2 x 3) 化学放射疗法 (CRT) 对LA-HNSCC具有过度的毒性.
研究的目的:
- 评估一种基于算法的化学放射选择策略,以优化LA-HNSCC中CRT.
- 为了确定哪些患者会从强化CRT或彻底手术中获益最多.
- 为了减少毒性,同时保持有利的生存和生活质量.
主要方法:
- 131名患有第三或第四阶段HNSCC的患者接受了40 Gy CRT (CDDP 80 mg/m2).
- 根据最初的反应,患者被分为响应者 (≥50%的瘤减少) 和非响应者.
- 响应者接受了额外的30 Gy CRT (CDDP 80 mg/m2);没有响应者接受了手术或额外的CRT.
主要成果:
- 一个算法将患者分为106个响应者 (Res-CRT) 和25个不响应者.
- 获得了有利的5年整体存活率 (73%) 和无喉食道功能障碍的存活率 (49%).
- 响应者 (Res-CRT) 的无进展生存期 (PFS) 比不响应者要好得多. 接受CRT (非Res-CRT) 的不响应患者的PFS和喉保护结果最差.
结论:
- 基于算法的化学放射选择准确地确定了LA-HNSCC中优化CRT或手术的候选人.
- 这一策略实现了有利的生存,喉的保存和生活质量.
- 它为LA-HNSCC提供了高剂量CDDPCRT的可行替代品.
相关概念视频
Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


